In lung cancer, transcriptional induction of ERBB3 causes intrinsic resistance to MEK inhibition in KRAS-mutant cancers (Sun et al., 2014), and acquired resistance to EGFR inhibitors was found to result from amplification of MET (Engelman et al., 2007). This evidence concerns the gene KRAS and lung carcinoma.